Grant Details

Grants Office Grantwriting service fee is currently unavailable for this grant
Get more information on grantwriting

Authority

Summary

History of Funding

None is available.

Additional Information

With deep expertise in pharmaceutical distribution, analytics, and information technology, McKesson is committed to using its industry know how to help address some of the multitude of issues contributing to the opioid epidemic. McKesson will work with pharmacies, policymakers, prescribers, manufacturers, and others to advance the following initiatives:

• Expedite development of a national prescription safety-alert system. To identify patients who are at risk for opioid overuse, abuse, addiction, or misuse, the company will invest in the development of a national system that uses prescription information to provide real-time alerts to pharmacists and, ultimately, prescribers, indicating when additional patient information may be needed before dispensing opioids. The system design will address shortcomings of existing state and federal clinical decision support systems and save time for pharmacists and prescribers. Implementation of the system is contingent on the U.S. Food and Drug Administration's (FDA) exercise of its Risk Evaluation and Mitigation Strategies (REMS) or other authorities. The company is nonetheless moving forward with development of the system.
• Facilitate e-prescribing. To reduce fraudulent or counterfeit prescriptions, during 2019 the company will stop selling opioids to customers1 who cannot accept e-prescribing of controlled substances and will engage with those customers who may need to make this transition. The company continues to advocate that Congress require mandatory e-prescribing of opioids.
• Support limited-dose packaging. To make it easier for doctors to prescribe and pharmacists to dispense in smaller doses, and to reduce potential for unused product, the company will proactively engage with all opioid manufacturing partners this calendar year to develop plans for limited-dose packaging.
• Fast-track distribution of new, non-opioid pain medications. To improve access to medicines, the company will work with manufacturing partners to facilitate immediate availability on a national basis of non-opioid pain medication once approved by FDA.
• Provide complimentary pharmacist training on opioid overdose reversal medications. The company will offer pharmacists complimentary training by independent medical experts on how to administer medications such as naloxone.

Contacts